# Minimal Change Disease

## Epidemiology & Pathophysiology

MCD represents the **most common cause of nephrotic syndrome in children (85–90%)** and a significant etiology in adults (10–15%). Peak childhood incidence occurs between ages 2–6 years.

### Pathogenesis

MCD is a **podocytopathy** characterized by functional podocyte injury without histologic abnormality on light microscopy:

- **Podocyte foot process effacement** on electron microscopy (EM) is the hallmark
- Loss of slit diaphragm proteins (ZO-1, nephrin, podocin) without structural damage
- Presumed immune mechanism: T-cell dysfunction producing a circulating permeability factor (CPF)
- Evidence: rapid proteinuria response to immunosuppression, association with Hodgkin lymphoma and allergies
- Proteinuria is **highly selective** (mainly albumin)

**📚 Key Point:** Foot process effacement is *reversible* with appropriate therapy — this distinguishes MCD from other podocytopathies and explains the excellent prognosis.

## Clinical Presentation

### Typical Features

- **Sudden onset** nephrotic syndrome (proteinuria \>3.5 g/day, typically 1–10 g/day)
- **Hypoalbuminemia** with resultant edema (periorbital, lower extremity, ascites)
- **Normal blood pressure** and **absence of hematuria** (key differentiator from other GN)
- **Normal complement levels** (C3, C4 normal)
- No systemic disease features

**📚 Clinical Pearl:** In children with nephrotic syndrome presenting with edema, proteinuria, hypoalbuminemia, normal creatinine, **no hematuria**, and normal complement, the presentation is highly predictive of MCD. Many pediatric nephrologists empirically treat with corticosteroids without biopsy. Adults and atypical features warrant biopsy.

## Diagnosis

### Laboratory Findings

- **Serum:** Hypoalbuminemia (often \<2 g/dL), decreased immunoglobulins, normal creatinine
- **Urinalysis:** Heavy proteinuria, **absent or minimal hematuria** (≤5 RBC/hpf)
- **Lipiduria:** Oval fat bodies, fatty casts (pathognomonic appearance)
- **Complement:** Normal C3, C4 (rules out immune-complex disease)
- **Serologies:** Negative ANA, ANCA, anti-GBM

### Kidney Biopsy

| Modality | Finding |
|----|----|
| **Light Microscopy** | Completely normal glomeruli (defining feature) |
| **Electron Microscopy** | Diffuse foot process effacement (hallmark). No electron-dense deposits. Normal GBM. |
| **Immunofluorescence** | Negative or trace staining (no immune complex deposits) |

## Treatment

### First-Line: Corticosteroid Therapy

| Population | Regimen | Response |
|----|----|----|
| **Pediatric** | Prednisone 60 mg/m²/day (max 80 mg) for 4–6 weeks, then taper | 90% achieve CR within 2 weeks |
| **Adult** | Prednisone 1 mg/kg/day (up to 80 mg) for 4–6 weeks, slow taper; total 8–12 weeks | 50–80% achieve CR (slower: 4–8 weeks) |

### Response Categories

| Response | Definition |
|----|----|
| **Complete Remission** | Proteinuria \<0.3 g/day, normal serum albumin |
| **Partial Remission** | Proteinuria 0.3–3.5 g/day (\>50% reduction) |
| **No Response** | Proteinuria \>3.5 g/day or \<50% reduction — consider alternative diagnosis |

### Steroid-Sparing Agents (for dependent/resistant disease)

- **Cyclophosphamide:** 2 mg/kg/day for 8–12 weeks (40–50% long-term remission)
- **Mycophenolate mofetil:** 1–1.5 g BID for 6–12 months
- **Calcineurin inhibitors** (tacrolimus, cyclosporine): effective for steroid-dependent disease
- **Rituximab:** increasingly used; can induce long-term remission in steroid-dependent/resistant cases

### Supportive Care

- Salt restriction (\<2–3 g/day)
- Diuretics for symptomatic edema (avoid excessive diuresis — risk of AKI)
- ACE-I or ARB to reduce proteinuria
- Statins for hyperlipidemia
- VTE prophylaxis if albumin \<2 g/dL with high-risk features

**📚 Key Point:** Steroid-dependent disease is common in MCD and does *not* indicate poor long-term prognosis if managed appropriately with steroid-sparing agents. The key is achieving sustained remission on minimal therapy.

## Prognosis

- **Pediatric:** 90–95% initial steroid response; normal renal function in \>95% long-term; ESRD \<5% at 20 years
- **Adult:** 50–80% achieve CR; excellent long-term survival (\>95% at 20 years if well-managed)
- **Relapses:** 50–80% of children experience at least one relapse

**📚 Clinical Pearl:** Always counsel patients that MCD has an excellent prognosis. Multiple relapses do not worsen long-term renal outcomes if managed appropriately. Focus shifts to minimizing corticosteroid burden.

## Key Differentiating Features

| Feature | MCD | FSGS | MPGN | Lupus GN |
|----|----|----|----|----|
| **LM** | Normal | Sclerosis | Proliferation | Proliferation |
| **Hematuria** | Absent/minimal | Present | Present | Present |
| **Complement** | Normal | Normal | Low (often) | Low |
| **Steroid Response** | Excellent (\>80%) | Poor (\<10%) | Variable | Variable |

## Complications

- **AKI:** From massive proteinuria, severe hypoalbuminemia, or overly aggressive diuresis
- **Thromboembolism:** From urinary loss of anticoagulants (protein C, S, antithrombin)
- **Infection:** Asplenia-like state from urinary loss of immunoglobulins; increased pneumococcal risk
- **Hyperlipidemia:** Increased hepatic lipoprotein synthesis; cardiovascular risk
- **Growth retardation (pediatric):** From prolonged corticosteroid therapy

## References

1.  Vivarelli M, et al. Minimal change disease. *CJASN*. 2017;12(2):332-345. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27940460/)
2.  KDIGO Glomerular Disease Work Group. KDIGO 2021 Clinical Practice Guideline. *Kidney Int*. 2021;99(3S):S1-S304. [DOI](https://doi.org/10.1016/j.kint.2021.05.021)
3.  Maas RJ, Deegens JK, Smeets B, et al. Minimal change disease and idiopathic FSGS: manifestations of the same disease. *Nat Rev Nephrol* 2016. [PubMed 27748392](https://pubmed.ncbi.nlm.nih.gov/27748392/).
4.  Hahn D, Samuel SM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. *Cochrane Database Syst Rev*. 2020;2020(8):CD001533. [DOI](https://doi.org/10.1002/14651858.CD001533.pub6) \| [PubMed](https://pubmed.ncbi.nlm.nih.gov/35659203/)
5.  Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. *Lancet*. 1974;2(7888):556-560. [PubMed](https://pubmed.ncbi.nlm.nih.gov/4140273/)

© Urine Nephrology Now — Clinical Mastery Series


---

[Website version](https://urinenephrology.org/mastery/glomerular/minimal-change-disease.html) · Markdown synchronized October 3, 2026.